Avid Bioservices Inc (CDMO)

[Krakonos]

CP, this is from PR:

Final data from a Phase I IST that evaluated bavituximab in combination with paclitaxel in patients with HER2-negative metastatic breast cancer has been submitted for publication and the company is currently evaluating opportunities to advance the clinical development of bavituximab in breast cancer.

You wrote:

Dr. Stopeck's paper has been filed for publication (see PR) which means it is in peer-review as we speak.

My way of thinking is that you CAN'T submit something for publication if it's still under peer review (as we speak) since it may not fly after all if "peers" will find something wrong.

Peregrine stated it has been submitted for publication, which IMO means that it has been reviewed by peers and OK'd to publish it. So review in this case is done and the green light was given to go ahead and publish it.

Just my opinion, I can be wrong after all.